Intraday, ISRG stock is trading at $488.04, down -2.62%, as investors price in recent European expansion and product rollouts on 06 Mar 2026. The move follows stronger-than-expected fiscal momentum but elevated valuation metrics; Intuitive Surgical, Inc. (ISRG) on the NASDAQ remains a leader in robotic surgery with visible AI-enabled features such as force feedback and case insights.

ISRG stock: Market snapshot and intraday flow

We see ISRG stock at $488.04 on the NASDAQ in the United States with a day range of $478.26–$490.65 and volume at 1,299,218 shares. The shares are below the 50-day average ($527.85) and 200-day average ($513.51), signaling short-term pressure versus the medium-term trend.

ISRG stock: Recent news and growth catalysts

Intuitive Surgical completed a major distribution acquisition in Southern Europe and is bringing Ion and da Vinci 5 to more centers, a move management says will deepen commercial reach and patient access. The strategic update and FDA clearances for cardiac uses support adoption, and coverage from outlets such as MarketWatch and Nasdaq highlights the Europe push as a near-term demand driver.

ISRG stock: Financials, valuation and key metrics

Intuitive reports EPS 7.86 and a trailing P/E of 63.19, with market cap near $176.39 billion. Revenue and free cash flow per share are strong—revenue per share TTM 28.36, free cash flow per share TTM 7.02—but valuation ratios (price/sales ~17.47, price/free cash flow ~70.59) imply high growth requirements.

ISRG stock: Technical setup and trading signals

Technicals show RSI 43.69, MACD histogram turning positive, and ADX 30.26 indicating a strong trend. Bollinger Bands run $479.16–$511.24; a close below the lower band would increase downside risk, while a sustained break above the 50-day average $527.85 would favor momentum buyers.

Meyka grade & ISRG stock forecast analysis

Meyka AI rates ISRG with a score out of 100: 79.76/100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a 1-year target of $602.22, a quarterly view of $519.47, and a monthly view of $356.69. Forecasts are model-based projections and not guarantees.

ISRG stock: Risks, opportunities and strategy for AI stocks investors

Opportunity: AI-enabled features in da Vinci 5 and Ion can expand procedure mix and recurring instrument revenue. Risk: high P/E and price/free cash flow ratios mean missed execution or slower adoption would pressure returns. For AI stocks strategy, position sizing should reflect robotics exposure and longer sales cycles in hospital procurement.

Final Thoughts

Key takeaways: ISRG stock trades at $488.04 intraday on the NASDAQ on 06 Mar 2026, pressured by near-term selling but supported by product approvals, European direct operations and strong cash generation. Meyka AI’s forecast model projects a 1-year price of $602.22, implying an upside of 23.39% versus today’s price. The quarterly model at $519.47 implies a smaller upside of 6.44%, while the monthly outlook at $356.69 would imply downside risk of -26.91%. Our Meyka grade (B+, score 79.76) balances robust margins, accelerating free cash flow growth and high valuation multiples. These targets assume steady da Vinci 5 and Ion adoption and no macro shock. Forecasts are model-based projections and not guarantees. We recommend monitoring adoption data, procedure volumes, and upcoming earnings and guidance for conviction in ISRG stock within AI stocks strategies.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.